|
|
|
|
Eur J Clin Pharmacol 2010,Aug,01;66(8):755-74; (PMID: 20582584)
[...]Despite significant progress in pharmacogenetic research, only a few drugs, such as cetuximab, dasatinib, maraviroc and trastuzumab, require a pharmacogenetic test before being prescribed. There are several gaps that limit the application of pharmacogenetics based upon the complex nature of the [...]
|
|
|
Am J Clin Pathol 2010,Aug,01;134(2):284-92; (PMID: 20660333)
[...]Of the 6 cases interpreted as immunohistochemically negative and FISH-positive, 2 were from patients known to be receiving trastuzumab at the time of biopsy, 1 was very close to the FISH equivocal category, and 4 cases had fewer than 1.5 CEP17 signals per cell (1 [...]
|
|
|
Bioconjug Chem 2010,Jul,21;21(7):1385-8; (PMID: 20557066)
[...] nanoparticles without apparent influence on their properties and with reasonable pharmacokinetics and therefore may be ideally suited for multimodality imaging. By binding a biotinylated anti-Her2 Herceptin antibody to provide tumor targeting, a biotinylated DOTA chelator labeled with (111)ln and a biotinylated Cy5.5 fluorophore to a [...]
|
|
|
J Clin Oncol 2010,Jul,20;28(21):e369-70; author reply e371; (PMID: 20479394)
|
|
|
J Clin Oncol 2010,Jul,20;28(21):3407-10; (PMID: 20530269)
|
|
|
J Clin Oncol 2010,Jul,20;28(21):e355-6; author reply e357; (PMID: 20458048)
|
|
|
Gynecol Oncol 2010,Jul,01;118(1):95-6; author reply 96-7; (PMID: 20172595)
|
|
|
Biomed Pharmacother 2010,Jul,01;64(6):390-5; (PMID: 20347572)
[...]CEM cells were cultured in three dimensional (3-D) geometry in the Hollow Fibre Bioreactor (HFB) device. The cells were treated with Herceptin, anti-HER-2 (clone CB-11) and lipoplex containing lipofectamine (LipA) and plasmid DNA. To identify the response to treatment, the viability was established using Trypan blue assays.[...]
|
|
|
Histopathology 2010,Jul,01;57(1):27-38; (PMID: 20584089)
[...]Dobson L, Conway C, Hanley A, Johnson A, Costello S, O'Grady A, Connolly Y, Magee H, O'Shea D, Jeffers M & Kay E (2010) Histopathology 57, 27-38 Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation Aims: Accurate determination of HER-2 status is critical to identify patients for whom trastuzumab treatment will be of benefit. Although the recommended primary method of evaluation is immunohistochemistry, numerous reports of variability in interpretation have raised uncertainty about the reliability of results.[...]
|
|
|
J Clin Pathol 2010,Jun,01;63(6):544-7; (PMID: 20418225)
[...]In this study, over 50% of the patients with vulvar Paget disease overexpress HER-2/neu. Anti-HER-2/neu-antibodies like trastuzumab may therefore be an interesting treatment option for HER-2/neu-positive vulvar Paget disease.[...]
|
 1 2 3 4 5 6 7 8 
|
|
